Overview Dividends

(COO) The Cooper Companies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2166485019

Contact Lenses, IUD, Fertility Consumables, Medical Devices

Health Care Supplies
Market Cap in USD: 16,342m
IPO / Inception: 1983-12-30
Return 12m vs S&P 500: -24.3%

EPS (Earnings per Share)

EPS (Earnings per Share) of COO over the last years for every Quarter: "2021-01": 3.17, "2021-04": 3.38, "2021-07": 3.41, "2021-10": 3.28, "2022-01": 3.24, "2022-04": 3.24, "2022-07": 3.19, "2022-10": 2.75, "2023-01": 2.9, "2023-04": 3.08, "2023-07": 3.35, "2023-10": 3.47, "2024-01": 0.85, "2024-04": 0.85, "2024-07": 0.96, "2024-10": 1.04, "2025-01": 0.92, "2025-04": 0.96, "2025-07": 1.1, "2025-10": 1.15,
EPS CAGR: -24.14%
EPS Trend: -81.3%
Last SUE: 1.63
Qual. Beats: 3

Revenue

Revenue of COO over the last years for every Quarter: 2021-01: 680.5, 2021-04: 719.5, 2021-07: 763.4, 2021-10: 759.1, 2022-01: 787.2, 2022-04: 829.8, 2022-07: 843.4, 2022-10: 848.1, 2023-01: 858.5, 2023-04: 877.4, 2023-07: 930.2, 2023-10: 927.1, 2024-01: 931.6, 2024-04: 942.6, 2024-07: 1002.8, 2024-10: 1018.4, 2025-01: 964.7, 2025-04: 1002.3, 2025-07: 1060.3, 2025-10: 1065.2,
Rev. CAGR: 8.40%
Rev. Trend: 97.3%
Last SUE: 0.30
Qual. Beats: 0

Dividends

Currently no dividends paid
Risk via 5d forecast
Volatility 26.9%
Value at Risk 5%th 39.6%
Relative Tail Risk -10.57%
Reward TTM
Sharpe Ratio -0.27
Alpha -26.04
CAGR/Max DD -0.05
Character TTM
Hurst Exponent 0.420
Beta 0.793
Beta Downside 0.664
Drawdowns 3y
Max DD 42.17%
Mean DD 14.97%
Median DD 10.94%

Description: COO The Cooper Companies January 02, 2026

The Cooper Companies (NASDAQ:COO) operates two distinct businesses: CooperVision, which designs and sells spherical, toric, and multifocal contact lenses for conditions such as astigmatism, presbyopia, and myopia; and CooperSurgical, which provides fertility-related consumables and devices, hormone-free contraception (e.g., the Paragard IUD), and cryostorage services for cord blood and tissue. Both segments distribute through eye-care professionals, hospitals, group purchasing organizations and authorized resellers.

In FY 2023 the company reported roughly $2.5 billion in revenue, with CooperVision contributing about 70 % and CooperSurgical the remainder; the contact-lens market is projected to grow at a 5-6 % CAGR through 2028, driven by rising myopia prevalence and an aging population, while the global fertility-assisted-reproduction market is expanding at ~7 % CAGR as delayed child-bearing becomes more common. A key operating metric is the average selling price (ASP) of lenses, which has risen modestly (≈3 % YoY) as premium multifocal and myopia-control products gain market share.

For a deeper quantitative assessment, you might explore the ValueRay platform’s detailed valuation models.

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (374.9m TTM) > 0 and > 6% of Revenue (6% = 245.6m TTM)
FCFTA 0.03 (>2.0%) and ΔFCFTA 1.16pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 24.28% (prev 23.84%; Δ 0.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.06 (>3.0%) and CFO 796.1m > Net Income 374.9m (YES >=105%, WARN >=100%)
Net Debt (2.67b) to EBITDA (1.02b) ratio: 2.62 <= 3.0 (WARN <= 3.5)
Current Ratio 1.89 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (198.1m) change vs 12m ago -1.49% (target <= -2.0% for YES)
Gross Margin 64.32% (prev 66.64%; Δ -2.31pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 33.12% (prev 31.63%; Δ 1.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 5.89 (EBITDA TTM 1.02b / Interest Expense TTM 109.1m) >= 6 (WARN >= 3)

Altman Z'' 4.72

(A) 0.08 = (Total Current Assets 2.11b - Total Current Liabilities 1.11b) / Total Assets 12.39b
(B) 0.62 = Retained Earnings (Balance) 7.64b / Total Assets 12.39b
(C) 0.05 = EBIT TTM 642.1m / Avg Total Assets 12.36b
(D) 1.75 = Book Value of Equity 7.26b / Total Liabilities 4.16b
Total Rating: 4.72 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 55.40

1. Piotroski 6.0pt
2. FCF Yield 2.28%
3. FCF Margin 10.60%
4. Debt/Equity 0.34
5. Debt/Ebitda 2.62
6. ROIC - WACC (= -3.42)%
7. RoE 4.54%
8. Rev. Trend 97.26%
9. EPS Trend -81.35%

What is the price of COO shares?

As of January 04, 2026, the stock is trading at USD 81.11 with a total of 2,229,568 shares traded.
Over the past week, the price has changed by -1.83%, over one month by +6.95%, over three months by +17.35% and over the past year by -10.53%.

Is COO a buy, sell or hold?

The Cooper Companies has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy COO.
  • Strong Buy: 9
  • Buy: 2
  • Hold: 8
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the COO price?

Issuer Target Up/Down from current
Wallstreet Target Price 90.5 11.6%
Analysts Target Price 90.5 11.6%
ValueRay Target Price 86.2 6.3%

COO Fundamental Data Overview December 31, 2025

Market Cap USD = 16.34b (16.34b USD * 1.0 USD.USD)
P/E Trailing = 44.1935
P/E Forward = 18.3486
P/S = 3.9933
P/B = 1.9653
P/EG = 2.1549
Beta = 1.049
Revenue TTM = 4.09b USD
EBIT TTM = 642.1m USD
EBITDA TTM = 1.02b USD
Long Term Debt = 2.46b USD (from longTermDebt, last quarter)
Short Term Debt = 85.6m USD (from shortTermDebt, last quarter)
Debt = 2.78b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.67b USD (from netDebt column, last quarter)
Enterprise Value = 19.02b USD (16.34b + Debt 2.78b - CCE 110.6m)
Interest Coverage Ratio = 5.89 (Ebit TTM 642.1m / Interest Expense TTM 109.1m)
FCF Yield = 2.28% (FCF TTM 433.7m / Enterprise Value 19.02b)
FCF Margin = 10.60% (FCF TTM 433.7m / Revenue TTM 4.09b)
Net Margin = 9.16% (Net Income TTM 374.9m / Revenue TTM 4.09b)
Gross Margin = 64.32% ((Revenue TTM 4.09b - Cost of Revenue TTM 1.46b) / Revenue TTM)
Gross Margin QoQ = 56.42% (prev 65.26%)
Tobins Q-Ratio = 1.53 (Enterprise Value 19.02b / Total Assets 12.39b)
Interest Expense / Debt = 0.88% (Interest Expense 24.4m / Debt 2.78b)
Taxrate = 27.57% (32.2m / 116.8m)
NOPAT = 465.1m (EBIT 642.1m * (1 - 27.57%))
Current Ratio = 1.89 (Total Current Assets 2.11b / Total Current Liabilities 1.11b)
Debt / Equity = 0.34 (Debt 2.78b / totalStockholderEquity, last quarter 8.24b)
Debt / EBITDA = 2.62 (Net Debt 2.67b / EBITDA 1.02b)
Debt / FCF = 6.16 (Net Debt 2.67b / FCF TTM 433.7m)
Total Stockholder Equity = 8.25b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.02% (Net Income 374.9m / Total Assets 12.39b)
RoE = 4.54% (Net Income TTM 374.9m / Total Stockholder Equity 8.25b)
RoCE = 6.00% (EBIT 642.1m / Capital Employed (Equity 8.25b + L.T.Debt 2.46b))
RoIC = 4.32% (NOPAT 465.1m / Invested Capital 10.78b)
WACC = 7.73% (E(16.34b)/V(19.13b) * Re(8.94%) + D(2.78b)/V(19.13b) * Rd(0.88%) * (1-Tc(0.28)))
Discount Rate = 8.94% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF Debug] Terminal Value 72.31% ; FCFE base≈375.5m ; Y1≈321.3m ; Y5≈249.6m
Fair Price DCF = 19.90 (DCF Value 3.90b / Shares Outstanding 196.0m; 5y FCF grow -17.55% → 3.0% )
EPS Correlation: -81.35 | EPS CAGR: -24.14% | SUE: 1.63 | # QB: 3
Revenue Correlation: 97.26 | Revenue CAGR: 8.40% | SUE: 0.30 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.07 | Chg30d=+0.029 | Revisions Net=+8 | Analysts=16
EPS current Year (2026-10-31): EPS=4.51 | Chg30d=+0.109 | Revisions Net=+14 | Growth EPS=+9.4% | Growth Revenue=+5.5%
EPS next Year (2027-10-31): EPS=4.94 | Chg30d=+0.132 | Revisions Net=+12 | Growth EPS=+9.7% | Growth Revenue=+5.4%

Additional Sources for COO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle